S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13

Syros Pharmaceuticals Stock Forecast, Price & News

-0.27 (-7.07%)
(As of 12/3/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
326,933 shs
Average Volume
817,686 shs
Market Capitalization
$219.91 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive SYRS News and Ratings via Email

Sign-up to receive the latest news and ratings for Syros Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Syros Pharmaceuticals logo

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc. engages in the development of gene control therapies for cancer and diseases. Its product candidates include SY-1425, SY-2101, and SY-5609. The company was founded by Richard A. Young, Nathanael S. Gray, and James E. Bradner on November 9, 2011 and is headquartered in Cambridge, MA.


Syros to Participate in Upcoming Investor Conferences
November 16, 2021 |  finance.yahoo.com
Earnings Preview For Syros Pharmaceuticals
November 4, 2021 |  benzinga.com
Cathie Wood is Dumping These 15 Stocks
September 30, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$15.09 million
Book Value
$1.71 per share


Net Income
$-84.04 million
Net Margins
Pretax Margin




Free Float
Market Cap
$219.91 million

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

2.11 out of 5 stars

Medical Sector

503rd out of 1,390 stocks

Pharmaceutical Preparations Industry

232nd out of 668 stocks

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -

Syros Pharmaceuticals (NASDAQ:SYRS) Frequently Asked Questions

Is Syros Pharmaceuticals a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syros Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Syros Pharmaceuticals stock.
View analyst ratings for Syros Pharmaceuticals
or view top-rated stocks.

How has Syros Pharmaceuticals' stock price been impacted by COVID-19 (Coronavirus)?

Syros Pharmaceuticals' stock was trading at $5.15 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, SYRS stock has decreased by 31.1% and is now trading at $3.55.
View which stocks have been most impacted by COVID-19

When is Syros Pharmaceuticals' next earnings date?

Syros Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, March 3rd 2022.
View our earnings forecast for Syros Pharmaceuticals

How were Syros Pharmaceuticals' earnings last quarter?

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) released its earnings results on Friday, November, 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.44) by $0.03. Syros Pharmaceuticals had a negative net margin of 434.32% and a negative trailing twelve-month return on equity of 77.65%. During the same quarter in the prior year, the firm posted ($0.43) EPS.
View Syros Pharmaceuticals' earnings history

What price target have analysts set for SYRS?

3 brokerages have issued 1-year price objectives for Syros Pharmaceuticals' shares. Their forecasts range from $14.00 to $23.00. On average, they expect Syros Pharmaceuticals' stock price to reach $18.00 in the next twelve months. This suggests a possible upside of 407.0% from the stock's current price.
View analysts' price targets for Syros Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Syros Pharmaceuticals' key executives?

Syros Pharmaceuticals' management team includes the following people:
  • Nancy A. Simonian, President, Chief Executive Officer & Director
  • Gerald E. Quirk, Chief Operating Officer
  • Jason Haas, Chief Financial Officer
  • Eric R. Olson, Chief Scientific Officer
  • David A. Roth, Chief Medical Officer

What is Nancy Simonian's approval rating as Syros Pharmaceuticals' CEO?

3 employees have rated Syros Pharmaceuticals CEO Nancy Simonian on Glassdoor.com. Nancy Simonian has an approval rating of 100% among Syros Pharmaceuticals' employees. This puts Nancy Simonian in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Syros Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Syros Pharmaceuticals investors own include Corbus Pharmaceuticals (CRBP), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), ImmunoGen (IMGN), VBI Vaccines (VBIV), Amarin (AMRN), Amicus Therapeutics (FOLD), Nektar Therapeutics (NKTR) and Pfizer (PFE).

When did Syros Pharmaceuticals IPO?

(SYRS) raised $60 million in an initial public offering on Thursday, June 30th 2016. The company issued 4,000,000 shares at $14.00-$16.00 per share. Cowen and Company and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is Syros Pharmaceuticals' stock symbol?

Syros Pharmaceuticals trades on the NASDAQ under the ticker symbol "SYRS."

Who are Syros Pharmaceuticals' major shareholders?

Syros Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.03%), Artal Group S.A. (3.23%), Altium Capital Management LP (2.05%), Geode Capital Management LLC (1.38%), Goldman Sachs Group Inc. (0.79%) and Millennium Management LLC (0.51%). Company insiders that own Syros Pharmaceuticals stock include Eric R Olson, Mark J Alles, Richard A Young and Srinivas Akkaraju.
View institutional ownership trends for Syros Pharmaceuticals

Which major investors are selling Syros Pharmaceuticals stock?

SYRS stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Morgan Stanley, Cubist Systematic Strategies LLC, Marshall Wace LLP, BlackRock Inc., Geode Capital Management LLC, Dimensional Fund Advisors LP, and Two Sigma Advisers LP.
View insider buying and selling activity for Syros Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Syros Pharmaceuticals stock?

SYRS stock was acquired by a variety of institutional investors in the last quarter, including Artal Group S.A., Altium Capital Management LP, Franklin Resources Inc., State Board of Administration of Florida Retirement System, LGT Capital Partners LTD., Summit Global Investments, SG Americas Securities LLC, and Ieq Capital LLC.
View insider buying and selling activity for Syros Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Syros Pharmaceuticals?

Shares of SYRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Syros Pharmaceuticals' stock price today?

One share of SYRS stock can currently be purchased for approximately $3.55.

How much money does Syros Pharmaceuticals make?

Syros Pharmaceuticals has a market capitalization of $219.91 million and generates $15.09 million in revenue each year. The company earns $-84.04 million in net income (profit) each year or ($1.62) on an earnings per share basis.

How many employees does Syros Pharmaceuticals have?

Syros Pharmaceuticals employs 103 workers across the globe.

What is Syros Pharmaceuticals' official website?

The official website for Syros Pharmaceuticals is www.syros.com.

Where are Syros Pharmaceuticals' headquarters?

Syros Pharmaceuticals is headquartered at 35 Cambridge Park Drive 4th Floor, CAMBRIDGE MA, 02139.

How can I contact Syros Pharmaceuticals?

Syros Pharmaceuticals' mailing address is 35 Cambridge Park Drive 4th Floor, CAMBRIDGE MA, 02139. The company can be reached via phone at (617) 744-1340 or via email at [email protected].

This page was last updated on 12/4/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.